Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute

תרגום אוטומטי מקומי · שפת המקור

Illustration generated by Business News; it is not a source photograph.

סיכום

OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…

שפת המקור: PR Newswire UK — News Releasesקראו את המקור →